{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-022186","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.791271+00:00","generated_at":"2026-06-02T04:37:27.400912+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sangamo Q1 net loss $49.1M on revenue collapse to $0.5M from $158M; cash runway only into Q3 2024","bullets":["Net loss of $49.1M vs net income $21.1M YoY; diluted EPS -$0.27 vs +$0.12.","Revenue fell to $0.5M from $158M, driven by termination of Biogen/Novartis collaborations.","Cash $54.4M at March 31 (down from $81M); raised ~$24M gross via direct offering.","Pfizer expects BLA/MAA submission for hemophilia A gene therapy in early 2025 if mid-2024 pivotal readout positive.","Fabry gene therapy STAAR study fully dosed; seeking collaboration partner before registrational trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-022186","json":"https://secwatch.observer/filing/0001628280-24-022186.json","markdown":"https://secwatch.observer/filing/0001628280-24-022186.md","text":"https://secwatch.observer/filing/0001628280-24-022186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024022186/0001628280-24-022186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024022186/sgmo-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:37:27.400912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9462120bdb495cff87ac42c8e9d5091edb603c46","claim":"SANGAMO THERAPEUTICS, INC reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter ended March 31, 2024 (the “Press Release”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024022186/0001628280-24-022186-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}